SCHEMBL3586683

SCHEMBL3586683

c1cnc2c(c1)ccc1nnnnc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 5/20 0.64
CCR8 P51685 5/20 0.64
LMNA P02545 4/20 0.64
CCR5 P51681 3/20 0.64
MMP2 P08253 2/20 0.64
TSHR P16473 2/20 0.64
CYP3A4 P08684 2/20 0.64
KDM4E B2RXH2 2/20 0.64
MAPT P10636 2/20 0.64
HTT P42858 2/20 0.64
SMN1; SMN2 Q16637 2/20 0.64
TDP1 Q9NUW8 2/20 0.64
GMNN O75496 1/20 0.64
TP53 P04637 1/20 0.64
HSP90AA1 P07900 1/20 0.64
CYP2D6 P10635 1/20 0.64
MMP9 P14780 1/20 0.64
ALOX15 P16050 1/20 0.64
NFKB1 P19838 1/20 0.64
MMP8 P22894 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1451059 0.90 LMNA (0.56) CCR1CCR8LMNACCR5MMP2
Phenanthroline SCHEMBL29444065 0.82 CCR1 (0.94) CCR1CCR8LMNACCR5MMP2
Phenanthroline SCHEMBL29354015 0.80 CCR1 (1.00) CCR1CCR8LMNACCR5MMP2
Phenanthroline SCHEMBL29367277 0.80 CCR1 (1.00) CCR1CCR8LMNACCR5MMP2
Phenanthroline SCHEMBL8845760 0.80 CCR1 (1.00) CCR1CCR8LMNACCR5MMP2
Phenanthroline SCHEMBL8312 0.80 CCR1 (1.00) CCR1CCR8LMNACCR5MMP2
SCHEMBL528130 0.78 LMNA (0.40) CCR1CCR8LMNACCR5MMP2
Phenanthroline SCHEMBL22982126 0.78 CCR1 (0.94) CCR1CCR8LMNACCR5MMP2
Phenanthroline SCHEMBL21300488 0.78 CCR1 (0.94) CCR1CCR8LMNACCR5MMP2
Phenanthroline SCHEMBL3790396 0.78 CCR1 (0.94) CCR1CCR8LMNACCR5MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9780310-B2 Heterocyclic compound for organic electroluminescent device and its application TOSOH CORPORATION (JP) 2017-10-03 US disclosed
US-9771362-B2 [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2017-09-26 US disclosed
US-20170066762-A1 [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2017-03-09 US disclosed
US-9394301-B2 [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-07-19 US disclosed
US-20160056388-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION TOSOH CORPORATION (JP) 2016-02-25 US disclosed
US-20150246915-A1 [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2015-09-03 US disclosed
US-9012633-B2 [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2015-04-21 US disclosed
EP-2217578-B9 [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE CANCER REC TECH LTD (GB) 2014-09-10 EP disclosed
US-20140155594-A1 [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2014-06-05 US disclosed
EP-2217578-B1 [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE CANCER REC TECH LTD (GB) 2013-12-04 EP disclosed
US-8431596-B2 [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2013-04-30 US disclosed
US-20100298339-A1 [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2010-11-25 US disclosed
EP-2217578-A1 [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE Cancer Research Technology Limited (GB) 2010-08-18 EP disclosed
WO-2009047514-A1 [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160056388-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION AOC2, AZI2, KCNH2 CCR1 4739/4885CCR8 3723/4885LMNA 2238/4885
US-20150246915-A1 [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use AXL, TYRO3, FLT3 CCR1 1556/4885CCR8 2115/4885LMNA 3833/4885
US-20100298339-A1 [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use AXL, TYRO3, FLT3 CCR1 1556/4885CCR8 2115/4885LMNA 3833/4885
US-20140155594-A1 [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use AXL, TYRO3, FLT3 CCR1 1556/4885CCR8 2115/4885LMNA 3833/4885
US-20170066762-A1 [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use AXL, TYRO3, FLT3 CCR1 1556/4885CCR8 2115/4885LMNA 3833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.